Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BPMC Blueprint Medicines Corp
- Stocks
- Healthcare
- NASDAQ: BPMC
Price (delayed)
$97.18
Market cap
$6.28B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.48
Enterprise value
$6.86B
Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company
Highlights
BPMC's gross profit has surged by 100% year-on-year and by 11% since the previous quarter
Blueprint Medicines's revenue has surged by 99% YoY and by 10% QoQ
The net income has shrunk by 132% QoQ but it has increased by 46% YoY
Blueprint Medicines's EPS has shrunk by 132% QoQ but it has increased by 48% YoY
BPMC's quick ratio is down by 23% year-on-year
BPMC's debt is up by 19% year-on-year
Key stats
What are the main financial stats of BPMC
Market
Valuations
Earnings
Shares outstanding
64.58M
Market cap
$6.28B
Enterprise value
$6.86B
Price to earnings (P/E)
N/A
Price to book (P/B)
18.15
Price to sales (P/S)
11.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.2
Revenue
$562.12M
Gross profit
$542.35M
Operating income
-$174.31M
Net income
-$155.73M
EBIT
-$123.51M
EBITDA
-$97.46M
Free cash flow
-$150.91M
Per share
Balance sheet
Liquidity
EPS
-$2.48
EPS diluted
-$2.48
Free cash flow per share
-$2.35
Book value per share
$5.35
Revenue per share
$8.77
TBVPS
$18.65
Total assets
$1.2B
Total liabilities
$853.47M
Debt
$713.33M
Equity
$342.13M
Working capital
$451.49M
Debt to equity
2.08
Current ratio
2.8
Quick ratio
2.67
Net debt/EBITDA
-5.94
Margins
Efficiency
Dividend
EBITDA margin
-17.3%
Gross margin
96.5%
Net margin
-27.7%
Operating margin
-31%
Return on assets
-13%
Return on equity
-48.9%
Return on invested capital
-7.9%
Return on capital employed
-13.1%
Return on sales
-22%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BPMC stock price
How has the Blueprint Medicines stock price performed over time
Intraday
-1.6%
1 week
-7.13%
1 month
18.44%
1 year
-10.3%
YTD
11.42%
QTD
9.8%
Financial performance
How have Blueprint Medicines's revenue and profit performed over time
Revenue
$562.12M
Gross profit
$542.35M
Operating income
-$174.31M
Net income
-$155.73M
Gross margin
96.5%
Net margin
-27.7%
The net income has shrunk by 132% QoQ but it has increased by 46% YoY
BPMC's net margin has dropped by 110% since the previous quarter but it has soared by 73% year-on-year
BPMC's gross profit has surged by 100% year-on-year and by 11% since the previous quarter
Blueprint Medicines's revenue has surged by 99% YoY and by 10% QoQ
Price vs fundamentals
How does BPMC's price correlate with its fundamentals
Growth
What is Blueprint Medicines's growth rate over time
Valuation
What is Blueprint Medicines stock price valuation
P/E
N/A
P/B
18.15
P/S
11.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.2
Blueprint Medicines's EPS has shrunk by 132% QoQ but it has increased by 48% YoY
The price to book (P/B) is 65% higher than the 5-year quarterly average of 11.2
Blueprint Medicines's equity has increased by 15% QoQ and by 10% YoY
Blueprint Medicines's revenue has surged by 99% YoY and by 10% QoQ
The P/S is 39% below the 5-year quarterly average of 18.6 and 15% below the last 4 quarters average of 13.3
Efficiency
How efficient is Blueprint Medicines business performance
Blueprint Medicines's return on sales has shrunk by 197% QoQ but it has surged by 77% YoY
BPMC's return on equity has dropped by 126% since the previous quarter but it has surged by 59% year-on-year
The company's return on assets has shrunk by 124% QoQ but it has surged by 51% YoY
The ROIC has soared by 56% YoY
Dividends
What is BPMC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BPMC.
Financial health
How did Blueprint Medicines financials performed over time
BPMC's total assets is 40% greater than its total liabilities
Blueprint Medicines's current ratio has decreased by 26% YoY
BPMC's quick ratio is down by 23% year-on-year
BPMC's debt is 108% greater than its equity
BPMC's debt is up by 19% year-on-year
Blueprint Medicines's equity has increased by 15% QoQ and by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.